Stockreport

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025 [Yahoo! Finance]

MetaVia Inc.  (MTVA) 
PDF DA-1726 Achieves Superior Lipid-Lowering Effects and Comparable Weight Loss to Pemvidutide in Pre-clinical Models CAMBRIDGE, Mass. Nov. 4, 2025 /PRNewswire/ -- MetaVi [Read more]